Bupropion
Bupropion has been studied in 30 papers since 2016: 4 trials and 13 observational studies in people, 11 reviews; 22 in the past year. It is an approved medicine. The newest paper, Nov 3, 2026: “From prescription to prognosis: longitudinal associations between different antidepressant classes on medical comorbidity in those with bipolar disorder”.
7 new papers in 30 daysSee all 61 papers on bupropion
At a glance
Independent labs found the same change in people. 9 independent labs in 9 countries; 208 trials, none about aging, 89 with no results posted.
“Bupropion was also associated with lower risk of MACE (HR 0.75; 95% CI 0.73-0.77)”
None of its findings points the other way.
- 9 independent labs in 9 countries
- 208 trials, none about aging, 89 with no results posted
- Funders: Alzheimer's Association and others
- 27 of 208 trials sponsored by its developers
- Human trial4
- Humans13
- In silico1
Studies in people
1 study gave bupropion to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on smoking abstinencep = 0.277 | Treated cohort12 weeks | 169 peopleBoth51.5±9 yearsMidlife adults; Patient cohorts | ESC Congress 2026 abstract, Oct 26, 2026 |
What did studies of bupropion find?
5Studies of bupropion measured 5 outcomes, among them smoking cessation, smoking abstinence and memory.
Smoking cessation
upin humans2
2 studies
Smoking cessation
upin humans2
Bupropion improves smoking cessation in StUD.
“Bupropion demonstrated efficacy in StUD but limited evidence in other disorders.”
Reviewin StUD
Research SquarePreprint
Bupropion increases smoking cessation in humans.
“Nicotine replacement, bupropion and varenicline were effective for smoking cessation, an outcome that can significantly lower cardiometabolic risk.”
Review
The British journal of psychiatry : the journal of mental science
Smoking abstinence
no changein humans1
1 study
Smoking abstinence
no changein humans1
Bupropion was not clearly linked with smoking abstinence in humans (p = 0.277).
“the relevant association in bupropion therapy was not significant (p = 0.277)”
HumansCompared with nicotine replacement therapy; adjusted for cardiovascular disease history, pack-years, and nicotine dependence12 weeksn = 169
ESC Congress 2026 abstract
Memory
upin humans1
1 study
Memory
upin humans1
Bupropion is linked with better memory in humans.
“Estradiol, naproxen, bupropion, and the combined use of triamterene and hydrochlorothiazide were found to enhance performance on 2 memory cognitive tests, immediate recall and delayed recall”
Humans
Medicine
Long-term smoking abstinence
upin humans1
1 study
Long-term smoking abstinence
upin humans1
Bupropion increases long-term smoking abstinence in humans (severe mental illness; compared with placebo or minimal care) (5 more per 100 achieving long-term smoking abstinence, 95% CI 1 to 10).
“bupropion (5 more per 100, 1 to 10; moderate certainty evidence) increased long term abstinence.”
Reviewsevere mental illness; compared with placebo or minimal care
Smoking cessation for people with severe mental illness: systematic review and network meta-analysis
BMJ medicine
Alzheimer's disease progression
downin humans1HR 0.57
1 study
Alzheimer's disease progression
downin humans1HR 0.57
Bupropion is linked with lower alzheimer's disease progression in humans (mild cognitive impairment) (HR 0.57 [0.49, 0.66]).
“bupropion (vs. escitalopram: difference: ‐0.06 [‐0.08, ‐0.05], P=0.002; hazard ratio [HR]: 0.57 [0.49, 0.66], P<0.001)”
Humansmild cognitive impairment
AAIC 2025 abstract
What is bupropion linked with?
4Studies link bupropion with 4 measures, among them major adverse cardiovascular events, smoking cessation and mortality.
Major adverse cardiovascular events
downin humans2HR 0.75
2 studies
Major adverse cardiovascular events
downin humans2HR 0.75
Bupropion is associated with major adverse cardiovascular events in humans (Nicotine or tobacco dependence; compared with no bupropion use) (HR 0.75; 95% CI 0.73-0.77).
“Bupropion was also associated with lower risk of MACE (HR 0.75; 95% CI 0.73-0.77)”
HumansNicotine or tobacco dependence; compared with no bupropion use3 yearsn = 152,436
Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion
AHA Scientific Sessions 2026 abstract
Bupropion is associated with major adverse cardiovascular events in humans.
“Both varenicline and bupropion individually showed lower mortality and MACE.”
HumansAfter acute coronary syndrome; added to nicotine replacement therapy versus nicotine replacement therapy alone
AHA Scientific Sessions 2026 abstract
Smoking cessation
upin humans1HR 2.25
1 study
Smoking cessation
upin humans1HR 2.25
Bupropion is associated with smoking cessation in humans (HR 2.25; 95% CI 2.06-2.45).
“Both therapies increased smoking cessation (varenicline HR 2.32; 95% CI 2.12-2.53; bupropion HR 2.25; 95% CI 2.06-2.45).”
HumansNicotine or tobacco dependence; compared with no bupropion use; cessation identified by ICD-10 code3 yearsn = 152,436
Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion
AHA Scientific Sessions 2026 abstract
Mortality
downin humans1
1 study
Mortality
downin humans1
Bupropion is associated with mortality in humans.
“Both varenicline and bupropion individually showed lower mortality and MACE.”
HumansAfter acute coronary syndrome; added to nicotine replacement therapy versus nicotine replacement therapy alone
AHA Scientific Sessions 2026 abstract
Alzheimer's disease
downin humans1HR 0.57
1 study
Alzheimer's disease
downin humans1HR 0.57
Bupropion is linked with a lower risk of Alzheimer's disease in humans (active comparator vs escitalopram, MCI cohort) (HR 0.57, 95% CI 0.49–0.66).
“Active comparator analyses indicated that bupropion (vs escitalopram; HR 0.57, 95% confidence interval [CI] [0.49, 0.66]”
Humansactive comparator vs escitalopram, MCI cohort
Alzheimer's & dementia (New York, N. Y.)
Has bupropion been tested in people?
0 of 208 about agingYes: 4 trials and 13 observational studies in people have been published, and 207 trials are registered.
Approved
Dec 30, 1985Discontinued
Oct 4, 1996Depressive Disorder, Major, major depressive episode
May 14, 1997Discontinued
Aug 28, 2003Depressive Disorder, Major, Seasonal Affective Disorder, depressive episodes
Apr 23, 2008Depressive Disorder, Major, Seasonal Affective Disorder, depressive episodes
Nov 10, 2011Depressive Disorder, Major
Repurposing
Phase 4Results posted22 trials
Phase 4Completed2 trials
Phase 3Terminated1 trial
Phase 4Completed5 trials
Phase 4Completed1 trial
Phase 4Results posted26 trials
40 of 82Fewer
In trials
Cigarette smoking
Phase 4Results posted5 trials
Tobacco use cessation
Phase 4Completed4 trials
Physiological sexual dysfunction
Phase 4Completed3 trials
Cigarette smoking-related carcinoma
Phase 4Recruiting1 trial
Roux-en-y gastric bypass
Phase 4Completed1 trial
Psychological sexual dysfunction
Phase 3Completed4 trials
All 14Fewer
Readouts due
- Mar 5, 2027
A Phase 1, First-in-human Study of VX-433
Phase 1Recruiting
- Mar 9, 2027
Stopped
NCT02238977TerminatedMajor depressive disorder
Study stopped due to difficulty recruiting
NCT03993457TerminatedMajor depressive disorder
terminated during COVID due to inability to see participants in person.
NCT00181896TerminatedDepression
Study was terminated due to lack of recruitment
NCT00119210TerminatedTobacco use disorder
We were unable to recruit sufficient numbers of patients and decided that the study protocol was not feasible to implement
NCT04531176TerminatedObesity
After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.
NCT01219673TerminatedCarcinoma
Low accrual.
All 7Fewer
Who is developing bupropion?
3 companies: Bausch Health Americas, Rose Research Center and Boehringer Ingelheim.
Trial sponsors
Company13 trialsPhase 43,672 people
Company12 trialsPhase 45,957 people
Company3 trialsPhase 44,695 people
Company1 trialPhase 4246 people
Company2 trialsPhase 31,581 people
Company2 trialsPhase 3510 people
Company2 trialsPhase 3206 people
Company1 trialPhase 3420 people